Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial-Reference-Cited by-同舟云学术

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Published:2017-09 Issue:9 Volume:18 Page:1202-1210
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Atkinson Victoria,Cebon Jonathan S,Jameson Michael B,Fitzharris Bernie M,McNeil Catriona M,Hill Andrew G,Ribas Antoni,Atkins Michael B,Thompson John A,Hwu Wen-Jen,Hodi F Stephen,Menzies Alexander M,Guminski Alexander D,Kefford Richard,Kong Benjamin Y,Tamjid Babak,Srivastava Archana,Lomax Anna J,Islam Mohammed,Shu Xinxin,Ebbinghaus Scot,Ibrahim Nageatte,Carlino Matteo S

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

3. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma;Hamid;N Engl J Med,2013

4. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy;European Journal of Cancer;2024-02

2. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

3. Programmed Cell Death Ligand 1 Immunohistochemical Expression and Cutaneous Melanoma: A Controversial Relationship;International Journal of Molecular Sciences;2024-01-04

4. Current drug therapy for colorectal cancer;Colorectal Cancer;2024

5. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV;Frontiers in Immunology;2023-12-07